Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.35
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.70 (5.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.35
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of options

8 Nov 2016 18:25

RNS Number : 6778O
Oncimmune Holdings PLC
08 November 2016
 

8 November 2016

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 8 November 2016, options over ordinary shares of the Company were awarded to certain Directors and certain PDMRs under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) as follows.

 

Name

Position

Number of share options awarded

Option exercise price per share (pence)

Percentage of issued share capital (%)

Meinhard Schmidt

Non-executive Chairman

120,370

108

0.236

Geoffrey Hamilton-Fairley

Chief Executive Officer

528,273

1

1.035

119,875

108

0.235

Andrew Millet

Chief Financial Officer

92,593

108

0.181

Andrea Murray

Chief Operational Scientist

41,667

108

0.082

Maarten Brusse

Chief Commercial Officer

74,074

108

0.145

 

The options are subject to the rules of the 2016 Share Option Plan and vest in five equal annual parts, the first fifth vesting on 7 November 2017 and each year thereafter for a further four years, subject to continued employment. Unless otherwise indicated in the table above, the options are exercisable at 108 pence, being the mid-market closing price of the Company's ordinary shares on 7 November 2016

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Meinhard Schmidt

2

Reason for the notification

a)

Position/status

 

Non-Executive Chairman, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

120,370

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

120,370

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Geoffrey Hamilton-Fairley

2

Reason for the notification

a)

Position/status

 

Chief Executive Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

528,273

N/A

119.875

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

648,148

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrew Millet

2

Reason for the notification

a)

Position/status

 

Chief Financial Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

92,593

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

92,593

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrea Murray

2

Reason for the notification

a)

Position/status

 

Chief Operational Scientist and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

41,667

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

41,667

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Maarten Brusse

2

Reason for the notification

a)

Position/status

 

Chief Commercial Officer and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

74,074

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

74,074

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIBDBSDGBGLI
Date   Source Headline
11th Sep 202012:14 pmRNSNew Incentivisation Scheme for Senior Management
3rd Sep 20207:00 amRNSCost-effectiveness study assessing EarlyCDT Lung
2nd Sep 20207:00 amRNSAutoantibody profiling agreement signed
13th Aug 202011:38 amRNSExercise of Options and Total Voting Rights
12th Aug 20207:00 amRNSAppointment of Joint Brokers
10th Aug 20207:00 amRNSEarlyCDT Lung Blood Test Featured on ITV News
7th Aug 20207:00 amRNSExercise of Options and Total Voting Rights
5th Aug 20207:00 amRNSFurther evidence for the use of the EarlyCDT Lung
31st Jul 20207:00 amRNSERJ publishes results from the ECLS study
27th Jul 20207:00 amRNSRoche Contract Expansion to Profile Autoantibodies
24th Jul 20202:52 pmRNSExercise of Options and Total Voting Rights
8th Jul 20207:00 amRNSPaper highlights potential of ImmunoINSIGHTS in RA
1st Jul 20207:00 amRNSAuthorisation for EarlyCDT Lung in Brazil
30th Jun 20207:00 amRNSExercise of Options
9th Jun 20203:54 pmRNSGrant of Options and PDMR notification
8th Jun 20207:00 amRNSHoldings in Company
5th Jun 20202:00 pmRNSPrice Monitoring Extension
5th Jun 20209:02 amRNSCORRECTION: Director/PDMR's Dealing
5th Jun 20207:00 amRNSDirector/PDMR's Dealing
4th Jun 20207:00 amRNSTrading Update for 12 months to 31 May 2020
2nd Jun 20204:09 pmRNSHolding(s) in Company
29th May 20202:40 pmRNSHolding(s) in Company
29th May 20207:00 amRNSNotice of Trading Update
28th May 202011:06 amRNSSecond Price Monitoring Extn
28th May 202011:00 amRNSPrice Monitoring Extension
28th May 20207:00 amRNSContract with Roche to Profile Autoantibodies
21st May 20207:00 amRNSEarlyCDT Lung Partnership Contract Signed
14th May 20207:00 amRNSFeatured Presentation at ASCO 2020 Virtual Meeting
12th May 20207:00 amRNSDrug Development Collaboration Agreement Signed
6th May 20208:56 amRNSPDMR Dealing
4th May 20205:08 pmRNSDirectorate Change
1st May 202010:32 amRNSGrant of Options and PDMR notification
24th Apr 20203:59 pmRNSDirector/PDMR Shareholding
7th Apr 202011:41 amRNSPDMR Dealing
1st Apr 202010:31 amRNSPDMR Dealing
25th Mar 202012:42 pmRNSPDMR Dealing
20th Mar 20202:09 pmRNSHolding(s) in Company
18th Mar 20205:42 pmRNSHolding(s) in Company
18th Mar 202012:19 pmRNSPDMR Dealing
17th Mar 202010:24 amRNSNICE concludes review of EarlyCDT Lung
13th Mar 202011:42 amRNSIssue of Equity
12th Mar 20206:31 pmRNSPDMR / PCA Dealings
4th Mar 20207:00 amRNSUS Commercial Launch
2nd Mar 20203:35 pmRNSDirector/PDMR's Dealing
21st Feb 20207:00 amRNS‘Winning in Business in Spain’ Award
18th Feb 202011:06 amRNSSecond Price Monitoring Extn
18th Feb 202011:00 amRNSPrice Monitoring Extension
14th Feb 20204:41 pmRNSSecond Price Monitoring Extn
14th Feb 20204:35 pmRNSPrice Monitoring Extension
14th Feb 202011:55 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.